Show simple item record

dc.contributor.author Maldonado, Rafael, 1961-
dc.contributor.author Calvé Pérez, Pablo, 1993-
dc.contributor.author García Blanco, Alejandra
dc.contributor.author Domingo Rodriguez, Laura, 1992-
dc.contributor.author Senabre, Eric
dc.contributor.author Martín García, Elena, 1975-
dc.date.accessioned 2021-11-17T07:38:32Z
dc.date.issued 2021
dc.identifier.citation Maldonado R, Calvé P, García-Blanco A, Domingo-Rodriguez L, Senabre E, Martín-García E. Vulnerability to addiction. Neuropharmacology. 2021;186:108466. DOI: 10.1016/j.neuropharm.2021.108466
dc.identifier.issn 0028-3908
dc.identifier.uri http://hdl.handle.net/10230/48998
dc.description.abstract Addiction is a chronic brain disease that has dramatic health and socioeconomic consequences worldwide. Multiple approaches have been used for decades to clarify the neurobiological basis of this disease and to identify novel potential treatments. This review summarizes the main brain networks involved in the vulnerability to addiction and specific innovative technological approaches to investigate these neural circuits. First, the evolution of the definition of addiction across the Diagnostic and Statistical Manual of Mental Disorders (DSM) is revised. We next discuss several innovative experimental techniques that, combined with behavioral approaches, have allowed recent critical advances in understanding the neural circuits involved in addiction, including DREADDs, calcium imaging, and electrophysiology. All these techniques have been used to investigate specific neural circuits involved in vulnerability to addiction and have been extremely useful to clarify the neurobiological basis of each specific component of the addictive process. These novel tools targeting specific brain regions are of great interest to further understand the different aspects of this complex disease. This article is part of the special issue on 'Vulnerabilities to Substance Abuse.'.
dc.description.sponsorship This work was supported by the Spanish Ministerio de Economía y Competitividad-MINECO (#SAF2017-84060-R-AEI/FEDER-UE), the Spanish Instituto de Salud Carlos III, RETICS-RTA (#RD12/0028/0023), the Generalitat de Catalunya, AGAUR (#2017-SGR-669), ICREA-Acadèmia (#2015) and the Spanish Ministerio de Sanidad, Servicios Sociales e Igualdad, Plan NAcional Sobre Drogas of the Spanish Ministry of Health (#PNSD-2017I068) to R.M., Fundació La Marató-TV3 (#2016/20-30) and Plan NAcional Sobre Drogas of the Spanish Ministry of Health (#PNSD-2019I006) to E.M-G. Figures are created with BioRender.com.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Elsevier
dc.relation.ispartof Neuropharmacology. 2021;186:108466
dc.rights © 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license(http://creativecommons.org/licenses/by-nc-nd/4.0/).
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.title Vulnerability to addiction
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1016/j.neuropharm.2021.108466
dc.subject.keyword Addiction
dc.subject.keyword Calcium imaging
dc.subject.keyword DREADD
dc.subject.keyword DSM-5
dc.subject.keyword Electrophysiology
dc.subject.keyword Inhibitory control
dc.subject.keyword Therapeutic approach
dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/SAF2017-84060-R
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

Compliant to Partaking